AU6951296A - C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen - Google Patents

C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen

Info

Publication number
AU6951296A
AU6951296A AU69512/96A AU6951296A AU6951296A AU 6951296 A AU6951296 A AU 6951296A AU 69512/96 A AU69512/96 A AU 69512/96A AU 6951296 A AU6951296 A AU 6951296A AU 6951296 A AU6951296 A AU 6951296A
Authority
AU
Australia
Prior art keywords
alkyl
mono
group
sulfonyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69512/96A
Other languages
English (en)
Inventor
Mitch Brenner
Wen-Bin Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of AU6951296A publication Critical patent/AU6951296A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
AU69512/96A 1995-08-08 1996-08-08 C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen Abandoned AU6951296A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US203895P 1995-08-08 1995-08-08
US60120396A 1996-02-14 1996-02-14
US601203 1996-02-14
US60918796A 1996-03-01 1996-03-01
US609187 1996-03-01
PCT/US1996/012876 WO1997005865A1 (en) 1995-08-08 1996-08-08 C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen
US002038 2001-11-02

Publications (1)

Publication Number Publication Date
AU6951296A true AU6951296A (en) 1997-03-05

Family

ID=27357060

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69512/96A Abandoned AU6951296A (en) 1995-08-08 1996-08-08 C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen

Country Status (9)

Country Link
EP (1) EP0845987A4 (zh)
JP (1) JPH11511137A (zh)
KR (1) KR19990036271A (zh)
CN (1) CN1198096A (zh)
AU (1) AU6951296A (zh)
BR (1) BR9609883A (zh)
CA (1) CA2229098A1 (zh)
MX (1) MX9801093A (zh)
WO (1) WO1997005865A1 (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0871710A4 (en) * 1995-08-08 2001-03-07 Univ Jefferson RECOMBINANT PROTEINASE C AND PROCESSES, METHODS AND USES
US5994351A (en) * 1998-07-27 1999-11-30 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
WO1998003164A1 (en) * 1996-07-22 1998-01-29 Monsanto Company Thiol sulfone metalloprotease inhibitors
IL128189A0 (en) * 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
US6037139A (en) * 1997-06-03 2000-03-14 Wisconsin Alumni Research Foundation System for assaying modulators of procollagen maturation
US6423729B1 (en) 1997-07-22 2002-07-23 Shionogi & Co., Ltd. Therapeutic or prophylactic agent for glomerulopathy
JP2001513484A (ja) * 1997-07-31 2001-09-04 ザ プロクター アンド ギャンブル カンパニー 非環式メタロプロテアーゼ阻害剤
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
US6107337A (en) * 1998-08-06 2000-08-22 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
JP2002531576A (ja) 1998-12-10 2002-09-24 エフ.ホフマン−ラ ロシュ アーゲー プロコラーゲンc−プロテイナーゼ阻害剤
PL349449A1 (en) * 1998-12-22 2002-07-29 Hoffmann La Roche Sulfonamide hydroxamates
US6492394B1 (en) 1998-12-22 2002-12-10 Syntex (U.S.A.) Llc Sulfonamide hydroxamates
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
US6506936B1 (en) 1999-02-25 2003-01-14 Fibrogen, Inc. N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
BR0009244A (pt) 1999-03-03 2002-04-16 Procter & Gamble Inibidores de metaloprotease di-hétero substituìdos
HUP0202199A2 (en) 1999-03-03 2002-10-28 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
US6462063B1 (en) 2000-02-04 2002-10-08 Fibrogen, Inc. C-proteinase inhibitors
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US7119203B2 (en) 2002-04-25 2006-10-10 Pharmacia Corporation Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
PT1511472E (pt) * 2002-05-29 2009-07-24 Merck & Co Inc Compostos úteis no tratamento de antrax e inibição do factor letal
EP1572645A2 (en) 2002-12-03 2005-09-14 Enobia Pharma Inc. Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
EA200601105A1 (ru) 2003-12-19 2006-12-29 Басф Акциенгезельшафт Замещённые бензоилом фенилаланин-амиды
JP2007537256A (ja) 2004-05-11 2007-12-20 メルク エンド カムパニー インコーポレーテッド N−スルホン化アミノ酸誘導体調製のためのプロセス
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
AU2008247488B2 (en) 2007-05-04 2014-02-27 Marina Biotech, Inc. Amino acid lipids and uses thereof
WO2009097893A1 (en) * 2008-02-04 2009-08-13 Proyecto De Biomedicina Cima, S.L. Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp
CR20210213A (es) 2018-10-30 2021-06-24 Gilead Sciences Inc Derivados de quinolina como inhibidores de la integrina alfa4beta7
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4687841A (en) * 1985-10-18 1987-08-18 Monsanto Company Peptide hydroxamic acid derivatives
US4925868A (en) * 1986-08-29 1990-05-15 Takeda Chemical Industries, Ltd. 4-Hydroxy-3-pyrrolin-2-ones and treatment of circulatory disorders therewith
US5292926A (en) * 1988-01-25 1994-03-08 Santen Pharmaceutical Co., Ltd. Cysteine derivatives
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
NZ229004A (en) * 1988-05-19 1993-09-27 Immunobiology Res Inst Inc Tetrapeptides having t cell helper acitivity
FR2655339B2 (fr) * 1989-04-19 1992-04-10 Medgenix Group Sa Composes et complexes utiles notamment en imagerie medicale.
GB9008078D0 (en) * 1990-04-10 1990-06-06 Beecham Group Plc Novel compounds
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5443815A (en) * 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
US5237057A (en) * 1992-04-06 1993-08-17 Biosite Diagnostics, Inc. Tetrahydrocannabinol derivatives and protein and polypeptide tetrahydrocannabinol derivative conjugates and labels
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5393902A (en) * 1994-04-26 1995-02-28 Lever Brothers Company, Division Of Conopco, Inc. Process for the preparation of bis(amidocarboxylic acids)

Also Published As

Publication number Publication date
CN1198096A (zh) 1998-11-04
CA2229098A1 (en) 1997-02-20
BR9609883A (pt) 1999-03-23
MX9801093A (es) 1998-04-30
WO1997005865A1 (en) 1997-02-20
EP0845987A4 (en) 2000-05-24
KR19990036271A (ko) 1999-05-25
JPH11511137A (ja) 1999-09-28
EP0845987A1 (en) 1998-06-10

Similar Documents

Publication Publication Date Title
AU6951296A (en) C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen
MXPA98001093A (en) Inhibitors of proteinase c for the treatment of diseases related to the overproduction of colag
US5639781A (en) Alcohol or aldehyde derivatives and their use
EP0358398B1 (en) Cycloalkyl-substituted glutaramide antihypertensive agents
US5442110A (en) Hydroxamic acid derivative
KR100432602B1 (ko) 매트릭스메탈로프로테아제억제제
JPH1160551A (ja) スルホニルアミノカルボン酸
AU2017251683A1 (en) Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
KR20000015785A (ko) 페닐설폰아미드 유도체
JP2000515493A (ja) パラ―置換フェニレン誘導体
EP0274453A2 (fr) Nouveaux composés à activité d'inhibiteurs de collagénase, procédé pour les préparer et compositions pharmaceutiques contenant ces composés
KR19980086893A (ko) 치환된 디아미노카복실산
WO1999017790A1 (en) PEPTIDE-CONTAINING α-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS
US6506936B1 (en) N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
WO1997012903A1 (en) Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
JPH08301833A (ja) 選択的トロンビン抑制剤
FI112660B (fi) Menetelmä matriksin metalloproteaasien inhibiittoreina käyttökelpoisten trisyklisten indolijohdannaisten valmistamiseksi
EP0343911A2 (en) Cycloalkyl-substituted glutaramide diuretic agents
WO1993014112A1 (en) Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
US6462063B1 (en) C-proteinase inhibitors
KR19980086989A (ko) 치환된 6- 및 7- 아미노-테트라하이드로이소퀴놀린 카복실산
RU2106356C1 (ru) Псевдопептиды или их соли, способы их получения, фармацевтическая композиция
PL198827B1 (pl) ω-Amidy N-arylosulfonyloaminokwasów, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie ω-amidów N-arylosulfonyloaminokwasów
HU206194B (en) Process for producing cyclomethylene-1,2-dicarboxylic acid derivatives and pharmaceutical compositions comprising same
EP0712838B1 (en) Acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted